Topkapi is joining forces with NTR, BNNVARRA and Banijay Rights on a new drama, Elixer, which lifts the lid on the pharmaceutical industry.
Production on the eight-part series, directed by Dana Nechushtan (Holland’s Hoop) is currently underway, and is set to air on NPO1 in 2025.
Written by Maaik Krijgsman in collaboration with Jaap Peter Enderlé, Franky Ribbens and Luca Izeboud, Elixer tells the story of Isabelle Rombauts, played by Hanna Verboom, as she is unexpectedly appointed the CEO of the family-owned company Rombauts Pharma, a prominent player in the international pharmaceutical market. Soon, she is confronted with serious malpractices and must weigh her own conscience against the interests of her influential family. A world full of intrigue, power struggles, and despair within the pharmaceutical industry unfolds. Elixer will be filmed until November and is set to broadcast on NPO 1 in 2025.
Frans van Gestel, Producer and Partner at Topkapi says: “The co-production model of Elixer brings together partners from multiple Europe markets, and we see this growth as the next step in our international ambitions. This tale of caution around the pharma industry is universal and all-too relatable, and we expect audiences across the eight countries who contributed to the show will be intrigued and engaged.”
Dana Nechushtan, Director, adds: “Elixer is a drama told from the perspective of powerful individuals in the big pharma industry. We delve into the minds of those responsible: CEOs, doctors, and politicians, emphasising the dubious practices which, at times, are too vast and abstract to comprehend. At the same time, this story is a personal and intimate one.”
Elixer was made possible with the support of NPO, NPO-fonds, the Creative Europe Programme – MEDIA of the European Union, the Netherlands Film Production Incentive, Screen Flanders, Belgian Tax Shelter, and Limburg Film Fonds, in co-production with Menuetto.